MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Ea
EQS-News: MorphoSys AG / Key word(s): ConferenceMorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024 09.01.2023 / 07:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, January 9, 2023 Morp...
Source: pharmiweb.com